Magnesium sulfate 50% (magnesium 2mmol/ml) solution for injection 10ml ampoules Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium sulfate 50% (magnesium 2mmol/ml) solution for injection 10ml ampoules

magnesium 2mmol/ml) solution for injection 10ml ampoules (martindale pharmaceuticals ltd - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Rennie Deflatine Chewable Tablets Calcium Carbonate 680mg Magnesium Carbonate 80mg Simeticone 25mg Írland - enska - HPRA (Health Products Regulatory Authority)

rennie deflatine chewable tablets calcium carbonate 680mg magnesium carbonate 80mg simeticone 25mg

bayer limited - calcium carbonate; magnesium carbonate; simeticone - chewable tablet - 680 mg/80 mg/25 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations; silicones

MAGNESIUM SULFATE 50 % WV INOVAMED Ísrael - enska - Ministry of Health

magnesium sulfate 50 % wv inovamed

inovamed ltd - magnesium sulfate as heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate 50%w/v inovamed is indicated for:1. the treatment of magnesium deficiency in hypomagnesaemia. 2. the prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutrition. 3. the control and prevention of seizures in severe pre-eclampsia. 4. the control and prevention of recurrent seizures in eclampsia

MAGNESIUM SULFATE KALCEKS 50 % Ísrael - enska - Ministry of Health

magnesium sulfate kalceks 50 %

a.l. medi-market ltd. - magnesium sulfate heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate kalceks 50% solution for injection or infusion is indicated for: the treatment of magnesium deficiency in hypomagnesaemiathe prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutritionthe control and prevention of seizures in severe pre-eclampsiathe control and prevention of recurrent seizures in eclampsia

Bisodol Antacid Chewable TabletsCalcium Carbonate 522mgMagnesium Carbonate Light 68mgSodium Hydrogen Carbonate 64mg Írland - enska - HPRA (Health Products Regulatory Authority)

bisodol antacid chewable tabletscalcium carbonate 522mgmagnesium carbonate light 68mgsodium hydrogen carbonate 64mg

teva b.v. - calcium carbonate; sodium hydrogen carbonate; light magnesium carbonate - chewable tablet - 522/68/64 milligram(s) - calcium compounds; calcium carbonate

ALENDRONATE PLUS D3 CAL alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alendronate plus d3 cal alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Ibandronic acid Accord Evrópusambandið - enska - EMA (European Medicines Agency)

ibandronic acid accord

accord healthcare s.l.u. - ibandronic acid - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - drugs for treatment of bone diseases - ibandronic acid is indicated in adults forprevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.treatment of tumour induced hypercalcaemia with or without metastases.treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.